Pipeline overview

To beat incurable diseases, Diaccurate is exploring new frontiers of oncology and immunology in search of daring novel therapeutic approaches able to save lives. Now in the clinic, the French biotech is currently developing three sole-in-class drug candidates: the first dual targeted therapy that reaches brain metastases (the dual PAM inhibitor DIACC3010), the first targeted chemotherapy (the KIF20A inhibitor DIACC2010 / DIACC2020), and the first CD4 immunotherapy (the anti-PLA2G1B antibody DIACC1010).

DIACC3010

Dual PAM inhibitor
In-licensed from Merck KGaA

Triple Negative Breast Cancer

| Small molecule | Phase II program by H2 2022
Discovery
Preclinical
Phase 1
Phase 2

Gastric cancer

| Small molecule | Phase II program by H2 2022
Discovery
Preclinical
Phase 1
Phase 2

Aggressive lymphomas

| Small molecule | Phase II program by H2 2022
Discovery
Preclinical
Phase 1
Phase 2

DIACC2010

KIF20A inhibitor
Proprietary program

AML

| Small molecule
Discovery
Preclinical
Phase 1
Phase 2

DIACC2020

KIF20A inhibitor
Proprietary program

Solid Tumors

| Drug Conjugate
Discovery
Preclinical
Phase 1
Phase 2

DIACC1010

PLA2G1B blocker
Proprietary program

HIV

| Monoclonal antibody
Discovery
Preclinical
Phase 1
Phase 2

Cancer

| Monoclonal antibody
Discovery
Preclinical
Phase 1
Phase 2